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Abnormalities in EEG gamma band oscillations (GBO, 30–80Hz) serve as a prominent bio-
marker of schizophrenia (Sz), associated with positive, negative, and cognitive symptoms.
Chronic, subanesthetic administration of antagonists of N-methyl-D-aspartate receptors
(NMDAR), such as ketamine, elicits behavioral effects, and alterations in cortical interneu-
rons similar to those observed in Sz. However, the chronic effects of ketamine on neocorti-
calGBOareunknown.Thus,hereweexaminetheeffectsofchronic(ﬁvedailyi.p.injections)
application of ketamine (5 and 30mg/kg) and the more speciﬁc NMDAR antagonist, MK-
801 (0.02, 0.5, and 2mg/kg), on neocortical GBO ex vivo. Oscillations were generated
by focal application of the glutamate receptor agonist, kainate (KA), in coronal brain slices
containing the prelimbic cortex.This region constitutes the rodent analog of the human dor-
solateral prefrontal cortex, a brain region strongly implicated in Sz-pathophysiology. Here
we report the novel ﬁnding that chronic ketamine elicits a reduction in the peak oscilla-
tory frequency of KA-elicited oscillations (from 47 to 40Hz at 30mg/kg). Moreover, the
power of GBO in the 40–50Hz band was reduced.These ﬁndings are reminiscent of both
the reduced resonance frequency and power of cortical oscillations observed in Sz clinical
studies. Surprisingly, MK-801 had no signiﬁcant effect, suggesting care is needed when
equating Sz-like behavioral effects elicited by different NMDAR antagonists to alterations in
GBO activity.We conclude that chronic ketamine in the mouse mimics GBO abnormalities
observed in Sz patients. Use of this ex vivo slice model may be useful in testing therapeutic
compounds which rescue these GBO abnormalities.
Keywords: gamma oscillations, NMDA receptors, ketamine, schizophrenia, prefrontal cortex
INTRODUCTION
Mounting evidence suggests that the symptoms of neuropsychi-
atric disorders, such as schizophrenia (Sz), arise from a failure
of the brain to properly integrate activity across local and dis-
tributed neuronal circuitry (1–3). Neuronal oscillations represent
an essential mechanism responsible for such neural integration,
providing temporal coordination of neuronal activity (4). In Sz
patients, numerous clinical studies have observed abnormalities
in oscillatory processes (5), particularly those in the gamma fre-
quency band (gamma band oscillations, GBO; 30–80Hz). GBO
activity has been suggested to be critical for a number of sensory
and cognitive tasks (6). As such, impaired GBO, particularly in
prefrontal cortical regions, likely underlie positive, negative, and
cognitive symptoms in Sz (3, 7).
Over the last few decades, administration of psychotomimetic
agents, such as the N-methyl-d-aspartate receptor (NMDAR)
antagonist, ketamine, have provided the most reliable and widely
used means to mimic Sz-like symptoms, and currently represents
the “gold-standard” for modeling this disorder in both humans,
andanimals(8–10).Recentinvivo rodentstudieshaveshownthat
acute systemic administration of NMDAR antagonists leads to a
signiﬁcant potentiation of spontaneous GBO activity in frontal
cortex (11–13). Such ﬁndings have been largely conﬁrmed ex vivo
by our lab and others (14, 15). However, chronic application of
NMDAR antagonists arguably represents a more useful means to
model Sz, since chronic administration causes structural alter-
ations in neocortical circuitry similar to those observed in Sz
patients (16, 17). However, to what extent chronic administra-
tion of ketamine and other NMDA receptor antagonists mimic
Sz-like GBO abnormalities is not well understood. Thus, here we
explore the effect of systemic,chronic administration of ketamine
and the more speciﬁc NMDAR antagonist, MK-801 on GBO. In
order to focus on changes occurring speciﬁcally in the neocortical
circuitry, experiments were performed ex vivo, in slices contain-
ing the mouse prelimbic cortex (PrL), the rodent analog of the
human dorsolateral prefrontal cortex (18),a region heavily impli-
catedinmanyof thecognitiveimpairmentsassociatedwithSz(19,
20). GBO were elicited in submerged neocortical slices using our
established method (15) utilizing brief, focal application of the
glutamate receptor agonist kainate (KA).
MATERIALS AND METHODS
ANIMALS
Adult (>P91) heterozygous GAD67-GFP “knock-in” mice (Swiss
Webster background), which express GFP under control of the
promoterforGAD67(21)of eithersexwereutilizedforthiswork.
AsdeterminedpreviouslyinMcNallyetal.(15),therearenosignif-
icantsex-dependentdifferencesinKA-elicitedGBOinthesemice.
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Whilewedidnottakespeciﬁcadvantageof theGFPlabelinginthe
GAD67-GFP line in this study, our previous work examining the
effectsofacuteNMDARantagonisttreatmentonGBOactivitywas
performed using this mouse line. Thus, we utilized the same line
for the chronic studies reported here, allowing us to more accu-
ratelycompareourpresentﬁndingstothosereportedearlier.Mice
were housed at the VA Boston Healthcare System, Brockton cam-
pusunderconstanttemperature(23°C)anda12h:12hlight–dark
cycle with food and water available ad libitum. All experiments
were carried out in accordance with the American Association for
Accreditation of Laboratory Animal Care’s policy on care and use
of laboratoryanimalsandwereapprovedbythelocalInstitutional
Animal Care and Use Committee.
Chronic drug administration was conducted similar to the
manner described in Behrens et al. (22). Mice were given daily
i.p. injections of either ketamine-HCl (5 or 30mg/kg), MK-801
(0.02,0.5or2mg/kg),oranequivalentvolumeofsaline(<0.5mL)
for 5days. The efﬁcacy of these dosages for producing altered
interneuronal parvalbumin and/or GAD67 expression reminis-
cent of that seen in postmortem Sz brains was determined in
previous studies (16, 23–25). Mice injected with NMDAR antag-
onists exhibited increased locomotion for 1–2h following treat-
ment, as would be expected given the previous behavioral liter-
ature using these agents (8). However, this behavioral response
was not characterized in detail. Twenty-four hours following the
ﬁnal drug/saline injection, animals were sacriﬁced and utilized
as described below. Injectable Ketamine-HCl was obtained from
Bioniche Pharma (Galway, Ireland), and MK-801 from Ascent
Scientiﬁc (Bristol, UK).
SLICE PREPARATION
Coronal slices containing the PrL were prepared as previously
described in McNally et al. (15). Brieﬂy, mice were deeply anes-
thetized using isoﬂurane, then quickly decapitated. The brain
was removed and placed into ice cold modiﬁed artiﬁcial cere-
brospinal ﬂuid (ACSF) containing: (in millimoles) 252 Sucrose,
1.8 KCl, 1.2 KH2PO4, 2 MgSO4, 25.6 NaHCO3, and 10 glu-
cose saturated with 95% O2/5% CO2. 450mm slices were cut
between C2.96 and C1.54mm with respect to bregma [accord-
ing to the Franklin/Paxinos atlas (26)] using a Vibratome 3000
(Vibratome, Bannockburn, IL, USA). Slices were then transferred
into a prechamber (BSC-PC; Warner Instruments) containing
ACSF: (in millimoles) 124 NaCl, 1.8 KCl, 1.2 KH2PO4, 2 CaCl2,
1.3 MgSO4, 25.6 NaHCO3, and 10 glucose, continuously bub-
bled with 95% O2/5% CO2 (pH 7.4). Slices were allowed to
recover for at least 1h before use. For recording,slices were trans-
ferred to a submersion-style recording chamber (RC27L; Warner
Instruments) and constantly perfused (5mL/min) with warm
ACSF (30°C).
ELICITATION OF GBO IN VITRO
As described in McNally et al. (15), extracellular ﬁeld potential
activity was recorded using glass micropipettes (2–5M2) ﬁlled
with ACSF and positioned s50mm deep in the PrL (Layer II/III).
Oscillatory activity was elicited by a brief (80ms @ 30 psi) focal
application of KA (1mM) onto the PrL slice in close apposition
to the location of the ﬁeld potential electrode using a picospritzer
(General Valve Corp.). Field potentials elicited by KA application
were ampliﬁed using the 100 gain DC-coupled current-clamp
modeof aMulticlamp700Bampliﬁer(AxonInstruments).Signals
weredigitizedat10kHzusingaDigidata1322A16-bitdataacqui-
sitionsystem(AxonInstruments),thenﬁlteredbetween1kHzand
0.1Hz using pClamp 9.2 (Axon Instruments) and stored on a PC
hard drive.
ANALYSIS OF KA-ELICITED OSCILLATIONS
Kainate-elicited oscillations were characterized using both time-
frequency, and power spectral density (PSD) analysis. Grand
average time-frequency plots (Figure 1) were generated in Igor
Pro (Wavemetrics), by performing short-time Fourier transform
analysis (1Hz resolution) on individual LFP records of elicited
oscillatory activity. Time-frequency data was then averaged across
all animals in each treatment group. For data presented in
Figures 2 and 3, PSD proﬁles were generated by Fourier trans-
form analysis of ﬁeld potential recordings using both Clampﬁt
(axon) and Igor Pro. PSD were calculated from a 30s epoch
of the ﬁeld potential trace starting 2.5s following application
of KA, following dissipation of the mechanically evoked tran-
sient. KA-elicited oscillations were generated three consecutive
times at 5min intervals. Only slices yielding consistent PSD pro-
ﬁles across all trials (<10% difference in peak power, frequency)
were used for analysis. To analyze the time course of oscilla-
tory activity, the 30s epoch of KA-elicited activity was broken
up into six 5s epochs; PSD proﬁles (1.2Hz resolution) for each
epoch were generated, and then averaged across the three tri-
als to provide the average PSD over each epoch for each slice.
Recordingswereperformedononetothreeslicesfromeachexper-
imental animal. For each animal, PSD data from individual slices
were averaged to give the average PSD proﬁle for each animal.
These values were then used for comparison between treatment
groups.
Three measures from each PSD segment were used to charac-
terize the oscillations: peak power,peak frequency,and total GBO
power. Peak power was deﬁned as the highest amplitude in the
averaged PSD (>10Hz, bins of 1.2Hz). The frequency at which
the peak power was observed was deﬁned as the peak frequency.
Total GBO power was determined by integration of averaged
PSD between 40 and 50Hz, which represents roughly the average
peakfrequencyof theoscillatoryresponseobservedundercontrol
(no drug treatment) conditions 5Hz. This narrow frequency
band was chosen to reduce variability of the PSD measures, when
compared between groups of animals, i.e., drug treated vs. saline
controls [note: this band is narrower than that used in our previ-
ousstudy(15)whereweperformedawithin-animal(within-slice)
comparison of the effects of NMDAR antagonists].
STATISTICAL ANALYSIS
Overall analysis of chronic drug effects were initially tested using
repeated measures ANOVA. Further analyses of the results were
performedusingStudent’st-testforstatisticalcomparisonofindi-
vidual epochs of oscillatory response. All statistical analysis was
performed using SPSS 10 (SPSS Inc.). Differences were consid-
ered to be signiﬁcant at p <0.05. Averaged values reported in this
manuscript are expressed as meanSEM.
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FIGURE 1 | Grand average of kainate (KA) elicited oscillatory
response in prelimbic cortex (PrL) slices prepared from mice
receiving chronic administration of NMDAR antagonists.
Time-frequency spectrograms show the average KA-elicited oscillatory
response from acute PrL slices obtained from mice receiving chronic
injections of saline (control), ketamine (5 and 30mg/kg), or MK-801
(0.02 and 2mg/kg). Note: the mechanical transient associated with KA
application appears as a thick red line due to oversaturation. Compared
to saline treated controls, the elicited response in slices from mice
chronically treated with 30mg/kg ketamine shows a reduction in the
peak frequency (see Figure 2) and in the power in the (40–50Hz) band,
which is almost absent in slices from drug treated mice 5–10s following
KA application. 5mg/kg ketamine treatment also appears to show a
slight decrease in the higher-frequency elicited response, while the
response at lower frequency bands appears elevated (not signiﬁcant).
MK-801 treated mice show a trend toward reduced power but no
change in peak frequency (see Figure 2 and text). Insets provide
representative examples of GBO signal traces recorded from acute
slices from mice in each treatment group (scale bar for insets:
x D200ms, y D50mV).
RESULTS
CHRONIC KETAMINE DECREASES THE PEAK FREQUENCY OF PrL GBO
Toevaluatetheeffectsof chronicketamineonKA-inducedoscilla-
tions, adult mice were given ﬁve daily, i.p. injections of ketamine,
a treatment paradigm similar to that previously observed to elicit
Sz-like alteration in neural circuitry (16, 23). Twenty-four hours
aftertheﬁnalinjection,KA-inducedoscillationsinlayerII/IIIwere
characterized from PrL slices collected from either drug treated
(n D9)orcontrolanimalswhichreceivedsalineinjections(n D7).
Visual inspection of a grand average of KA-elicited oscillations
recorded from animals receiving chronic ketamine (30mg/kg)
injections revealed a clear reduction in the KA-elicited oscillatory
response when compared to saline treated controls (Figure 1).
This data was initially analyzed using the method employed in
our earlier acute NMDAR antagonist study (15), which exam-
ined the ﬁrst 5s of oscillatory activity immediately following
the decay of the DC transient caused by KA application (2.5–
7.5s following KA application). This analysis revealed a signiﬁ-
cant (t13 D3.74, p <0.01) decrease in the peak frequency (saline:
47.41.2Hz; ketamine: 40.41.3Hz) of elicited oscillations in
slicesfromchronicketaminetreatedmice(Table1:epoch1).Both
thepeakpowerandtotalGBOpowerwithintheﬁrst5salsotended
to decrease, but these effects were not statistically signiﬁcant
(t13 D1.24,p D0.24 and t13 D1.18,p D0.26 respectively).
Visual inspection of the grand averages suggested that oscilla-
tory activity elicited in 30mg/kg chronic ketamine treated slices
decayed faster than in saline treated animals. Thus, to determine
if chronic ketamine treatment impaired the ability of the PrL slice
to maintain the KA-elicited GBO, we additionally analyzed the
ﬁrst 30s of elicited oscillatory activity subdivided into 5s epochs
(Figure 2; Table 1). Using this analytical method, a repeated
measures ANOVA observed a signiﬁcant reduction in both the
www.frontiersin.org September 2013 | Volume 4 | Article 106 | 3 
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FIGURE 2 | Chronic ketamine treatment leads to decreases in the
power and peak frequency of KA-elicited PrL oscillations. Graphs show
the effects of chronic ketamine given at daily doses of 5mg/kg (blue) or
30mg/kg (red) on (A) total GBO power (40–50Hz), (B) peak power, and
(C) peak frequency across 30s of the elicited oscillatory response recorded
from acute PrL slices. Compared to saline treated controls (black), mice
receiving 30mg/kg ketamine showed a signiﬁcant decrease in both total
GBO power (between 5 and 20s; seeTable 1) and the peak frequency of
elicited activity. No change was observed in peak power. At 5mg/kg, chronic
ketamine had no signiﬁcant effect on total GBO power or peak power.
While a decrease in peak frequency was still apparent at this concentration,
this effect was only signiﬁcant in the 20–25 and 25–30s epochs.
peak frequency of elicited oscillations (F1,13 D52.77; p <0.01),
and total GBO power (F1,13 D9.99; p <0.01), across the full 30s
of KA-elicited activity. No effect was observed on peak power
(F1,13 D0.46; p D0.51). Further statistical analysis, comparing
each epoch individually, showed that the signiﬁcant decrease in
peak frequency observed above was maintained throughout all
periods of analyzed activity. While total GBO power was reduced
in chronic ketamine treated animals throughout the entire 30s of
analyzedactivity,thisreductionwasonlystatisticallysigniﬁcantin
thesecond(5–10s;t13 D3.09,p <0.01),third(10–15s;t13 D2.18,
FIGURE 3 | Chronic MK-801 treatment does not signiﬁcantly alter
KA-elicited PrL oscillations. Graphs show the effects of chronic MK-801
given at daily doses of 0.02mg/kg (blue) or 2mg/kg (red) on (A) total GBO
power (40–50Hz), (B) peak power, and (C) peak frequency across 30s of
the elicited oscillatory response recorded from acute PrL slices, compared
to saline treated controls (black). At both concentrations chronic MK-801
treatment resulted in no signiﬁcant alteration of KA-elicited oscillatory
activity.
p <0.05), and fourth (15–20s; t13 D2.30, p <0.05) epochs. No
signiﬁcant change in peak power was seen during these periods.
Chronic treatment with a lower concentration of ketamine
(5mg/kg, n D5), using the same dosing regimen described above
conversely appeared to lead to a mild potentiation of the power
of the KA-elicited oscillatory response (Figure 1). Nevertheless,
analysis of elicited oscillations from these mice revealed that the
signiﬁcant decrease in peak frequency observed with 30mg/kg
ketamine was also evident at this lower dose (repeated measure
ANOVA;F1,9 D6.95;p <0.05).Thisdecreasewasofasimilarmag-
nitudeasobservedwiththehigherketaminedosewhencompared
across all epochs of analyzed activity at 5mg/kg, however, it was
only signiﬁcant in epochs 5 and 6 (t9 D2.28, p <0.05; t9 D2.34,
p <0.05, respectively), and reached a trend level of signiﬁcance
Frontiers in Psychiatry | Schizophrenia September 2013 | Volume 4 | Article 106 | 4 
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in epochs 1, 2, 3, and 4 (t9 D1.87, p D0.10; t9 D1.98, p D0.08;
t9 D1.70,p D0.13; t9 D1.75,p D0.12,respectively). 5mg/kg ket-
amine did not lead to a decrease in the GBO power of KA-
elicited oscillations (Figure 2). Similarly, no signiﬁcant changes
were found in peak power, compared to saline controls across
the entire 30s of elicited oscillations analyzed (repeated mea-
sures ANOVA). Comparison of individual epochs for total GBO
and peak power did reveal a signiﬁcant increase in peak power
in the fourth epoch (15–20s; t9 D 2.54; p <0.05) and a trend
level increase in the third (10–15s; t9 D 1.73; p D0.12) and ﬁfth
(20–25s; t9 D 1.71; p D0.12) epochs, however.
CHRONIC MK-801 REVEALED NO STATISTICALLY SIGNIFICANT EFFECT
ON PrL GBO
While ketamine is commonly used recreationally and clinically to
elicit Sz-like effects, several other drugs which inhibit NMDAR
activity have also been used to elicit Sz-like behavioral effects in
animals(8,9).Thus,wealsoexaminedtheeffectofMK-801,anon-
competitiveNMDARantagonistwhichismoreselectivethanketa-
mine,sinceketaminehaseffectsonanumberof otherneurotrans-
mitterreceptors(15,27,28).Previousstudieshaveshownthatdaily
injections of 0.02mg/kg MK-801,were sufﬁcient to induce Sz-like
alterations in neural circuitry, and behavioral effects (24). Thus,
we gave mice ﬁve daily, i.p. injections of MK-801 (0.02mg/kg)
or saline, as above. Twenty-four hours after the ﬁnal injection,
KA-induced oscillations were characterized from PrL slices from
both drug treated (n D7) and saline control (n D7) animals. As
shown in Figure 1, the grand average of KA-elicited oscillations
recorded in slices from MK-801 mice also suggested an overall
reduction in elicited oscillatory response. Despite this, repeated
measure ANOVA analysis of the elicited activity revealed no sig-
niﬁcant effect on total GBO power (F1,11 D3.83; p D0.08), peak
frequency (F1,11 D1.66; p D0.22), or peak power (F1,11 D0.97;
p D0.35). Comparing across individual epochs (Table 1), while
the average GBO power was lower than that observed in saline
controls (Figure3A),these decreases reached only a trend level of
signiﬁcanceinepochs3,4,5,and6(t11 D1.70,p D0.12;t11 D1.61,
p D0.14; t11 D1.79, p D0.10; t11 D1.63, p D0.13, respectively).
Additionally,nosigniﬁcant(p >0.05)effectwasobservedonpeak
power, or peak frequency across the entire range of analyzed
KA-elicited activity (Figures 3B,C).
To ensure that the observed lack of effect was not caused
by the dose of MK-801 being too low, the above experiments
were repeated using ﬁrst 0.5mg/kg (n D4; data not shown) and
then 2mg/kg (n D3; Figure 3). As above, neither higher dose
of MK-801 had a signiﬁcant effect on total GBO power, peak
power,or peak oscillatory frequency with either repeated measure
ANOVA,or individual epoch analysis.Additionally,increasing the
length of chronic drug treatment from 5 to 14days of daily i.p.
injectionsof 2mg/kgMK-801(n D4)hadnoeffectoninvitro PrL
oscillatory activity compared to saline controls (data not shown).
DISCUSSION
The results reported in this study represent the ﬁrst investigation
of the effects of chronic (5days) application of NMDAR antago-
nists,ketamine,and MK-801,on gamma band oscillations (GBO)
in the adult mouse neocortex, ex vivo. There were three main
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ﬁndings:(1)Administration of chronic subanesthetic ketamine at
30 and 5mg/kg reduced the peak frequency of the elicited oscil-
lations; (2) Chronic ketamine at 30mg/kg also reduced the power
of corticalGBOwithinthe40–50Hzband;(3)Somewhatsurpris-
ingly,the effect of ketamine was not mimicked by a more selective
NMDARantagonist,MK-801.Inthefollowingsectionswediscuss
these three ﬁndings in more detail.
CHRONIC KETAMINE REDUCED THE PEAK OSCILLATORY FREQUENCY
OF GBO
Several studies have suggested that the neocortical circuitry has
an intrinsic resonance frequency (29, 30). Interestingly, each cor-
ticalareaappearstohaveitsowndominantfrequencywithfrontal
cortices showing a resonance frequency in the beta/gamma bands
(30).Although most studies of GBO in Sz focus on changes in the
power of oscillations, there is some evidence that Sz is also asso-
ciated with a change (decrease) in the peak resonance frequency
of cortical circuits. Several studies have reported a reduced 40Hz
response to auditory steady-state stimulation and a trend toward
an increased response at 20Hz (31, 32). Similarly, visual Gestalt
stimuli elicit a lower frequency GBO response in schizophren-
ics than in healthy individuals (33). More recently, Tononi and
colleagues used transcranial magnetic stimulation to probe the
natural oscillatory frequency of cortical circuits in Sz (34). Inter-
estingly, Sz subjects showed a signiﬁcant slowing in the peak fre-
quency of cortical oscillations,with the maximal decrease (10Hz)
occurring in the prefrontal cortex. Furthermore, the prefrontal
natural frequency of individuals with Sz was slower than in any of
the healthy control subjects and was correlated with both positive
and negative symptoms.
While our previous ﬁndings with acute ketamine (15) are not
directly comparable to our current chronic ﬁndings, due to the
different routes of ketamine administration (bath application vs.
systemic),itisstrikingthatasimilardecreaseinthepeakoscillatory
frequency of KA-elicited oscillations was observed in both exper-
iments. Thus, acute or chronic ketamine application reduced the
natural resonance frequency of prefrontal cortical circuits,similar
to ﬁndings in Sz patients (34). This downward shift in the oscil-
latory frequency would impair the ability of the circuit to receive
and process input in the normal GBO range,as it could no longer
reliablyfollowneuronalinputatsuchhighfrequencies.Thiswould
resultinreduced/inappropriatesynchronizationof neuralactivity,
which would likely contribute to both the psychosis and impaired
cognition observed in clinical studies, as well as Sz-like behaviors
in animal studies.
CHRONIC KETAMINE REDUCED THE POWER OF NEOCORTICAL GBO
Many studies of GBO in Sz patients have shown reductions in the
power of evoked GBO in a variety of sensory or cognitive para-
digms (35, 36). Our results here in the mouse prefrontal cortex
and those of Ferrarelli et al. (34), in Sz patients suggest that one
reason for such decreased GBO power may be a reduction in the
peakresonancefrequencyofcorticalcircuitry.Anotherreasonmay
be increased spontaneous, background broadband power due to
increased excitability of principal neurons, as observed in genetic
modelswithreducedNMDARexpressioninparvalbumin-positive
interneurons [see Ref. (37–39)]. In our study, with 30mg/kg
chronic ketamine we did not observe a broadband increase in
power, but rather a decrease in a narrow 40–50Hz band around
the peak resonance frequency, presumably due to the reduction
in this peak frequency (see above). Similarly, in vivo, in adult
animals,chronicketaminereducedGBOactivityinthehippocam-
pus (13). In our study, with the lower dose of 5mg/kg, the data
plottedinFigures1and2appearedtoshowincreasedpowercom-
pared to saline controls,particularly notable in the 15–20s epoch.
Despite this,statistical analysis (repeated measuresANOVA) indi-
cated that overall this effect was not signiﬁcant. Thus, we do
not believe there is any physiological relevance to the elevated
peak power measures observed with 5mg/kg ketamine treatment.
Together, these results with 30 and 5mg/kg ketamine suggest that
a higher dose is necessary to observe Sz-like reductions in GBO
power.
CHRONIC MK-801 APPLICATION HAD NO STATISTICALLY SIGNIFICANT
EFFECT ON PrL GBO
Surprisingly, we found that chronic treatment with MK-801, a
more speciﬁc NMDAR antagonist, did not reproduce the Sz-like
impairment in elicited PrL GBO caused by chronic ketamine.
Increasing the concentration of MK-801 or the duration of appli-
cation did not change the response. Disparity in the efﬁcacy
of different NMDAR antagonists in mimicking Sz-like effects
have also been observed in other studies. For instance, a recent
study compared the behavioral effects of chronic PCP, a simi-
larly promiscuous pharmacological agent to ketamine, and MK-
801 in rodents (40). This study found that MK-801 treatment
did not replicate the full spectrum of behavioral impairments
induced by PCP. What accounts for these differences between
Ketamine/PCP and MK-801? One possibility is that chronic sup-
pression of NMDAR functionby itself may notbe enoughto elicit
thebehavioral/electrophysiologicaleffect.Ketamine,inparticular,
hasactionsonseveralotherneurotransmitterreceptorssuchasD2
receptors,5-HT2 receptors,and GABAA receptors (15,27,28,41).
Another possibility is that differences in the pharmacokinetics of
these drugs affect the results. Thus, differences in the peak con-
centration, tissue penetration, and duration of action may affect
the resultant changes in neocortical circuitry. While the precise
mechanism has yet to be deﬁned, our results, and those of oth-
ers, suggest that chronic ketamine better models Sz-like changes
in cortical function than chronic MK-801.
CONCLUSION
Hereweshow,exvivo,thatchronicketamineat30mg/kgresultsin
Sz-likeimpairmentofboththefrequencyandpowerofKA-elicited
GBOinthePrL.Thiscombinedreductioninpowerandfrequency
is reminiscent of earlier clinical ﬁndings associated with cognitive
deﬁcits in Sz patients (31, 33–35). Our observation of these ﬁnd-
ings in an acute slice preparation provide strong evidence that the
chronic ketamine mediated effects are mediated by local circuit
alterations in the PrL. While important in establishing the locus
of changes in oscillatory activity, one important limitation when
comparing our ex vivo approach with clinical studies is that our
slice preparation lacks input from other brain regions important
in generating GBO activity in vivo. Thus,future studies testing the
effect of chronic ketamine in vivo, utilizing transcranial magnetic
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stimulation, or other means, to generate GBO will be important
for corroborating our results.
Acutely, NMDAR blockade leads to increased excitability of
pyramidal neurons (42), altering the balance of excitation and
inhibition in the cortical circuitry. Thus, we speculate that in our
system chronic ketamine treatment leads to changes in the corti-
cal circuitry in the PrL resulting over time in circuit dysfunction,
perhapsthroughexcitotoxicity(43)and/orupregulationof oxida-
tive pathways (25). While we did not directly examine the cel-
lular mechanisms behind this effect in this study, computational
modeling suggests that either reductions in the number of PV
interneurons or a reduction in GAD67 could account for our
ﬁndings of reduced GBO power and peak frequency (44, 45).
Our ﬁndings support the idea that deﬁcits in executive function
observedwithchronicadministrationof ketamineinhumansand
animals (8, 9, 46–48) are due to an impaired ability of neocor-
tical circuitry to generate and/or maintain the proper frequency
oscillations and synchronicity necessary to bind together relevant
information.
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